Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Other Non Operating Income (2016 - 2026)

Ocular Therapeutix has reported Other Non Operating Income over the past 13 years, most recently at $1.8 million for Q1 2026.

  • For Q1 2026, Other Non Operating Income rose 402.31% year-over-year to $1.8 million; the TTM value through Mar 2026 reached $2.5 million, down 45.82%, while the annual FY2025 figure was $29000.0, 100.1% up from the prior year.
  • Other Non Operating Income for Q1 2026 was $1.8 million at Ocular Therapeutix, up from $1.7 million in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $14.2 million in Q3 2023 and troughed at -$28.0 million in Q1 2024.
  • A 5-year average of -$1.1 million and a median of -$1000.0 in 2023 define the central range for Other Non Operating Income.
  • Biggest five-year swings in Other Non Operating Income: surged 1418900.0% in 2023 and later tumbled 2794900.0% in 2024.
  • Year by year, Other Non Operating Income stood at $1000.0 in 2022, then tumbled by 1419200.0% to -$14.2 million in 2023, then surged by 153.65% to $7.6 million in 2024, then tumbled by 77.08% to $1.7 million in 2025, then rose by 4.99% to $1.8 million in 2026.
  • Business Quant data shows Other Non Operating Income for OCUL at $1.8 million in Q1 2026, $1.7 million in Q4 2025, and -$938000.0 in Q3 2025.